Anti-Saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy

Annals of the Rheumatic Diseases

Volumn 62, Issue 5, 2003, Pages 455-459

  Hoffman, I E A ^a   Demetter, P ^a   Peeters, M ^a   De Vos, M ^a   Mielants, H ^a   Veys, E M ^a   De Keyser, F ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FUNGUS ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; HLA B27 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INTESTINE BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SACCHAROMYCES CEREVISIAE; SAMPLING; SCREENING; SPONDYLOARTHROPATHY; STATISTICAL SIGNIFICANCE; IMMUNOLOGY; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; SYNOVITIS; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, FUNGAL; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HLA-B27 ANTIGEN; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; SACCHAROMYCES CEREVISIAE; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; SYNOVITIS; TIME FACTORS;

EID: 0037404927     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.5.455     Document Type: Article

References (34)

1. Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR, et al. Antibody to Saccharomyces cerevisiae (baker's yeast) in Crohn's disease. BMJ 1988;297:1105-6.
2. Sendid B, Colombel F, Jacquinot PM, Faille C, Fruit J, Cortot A, et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol 1996;3:219-26.
3. McKenzie H, Main J, Pennington CR, Parrat D. Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease. Gut 1990;31:536-8.
4. Quinton J-F, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42:788-91.
5. Hoffenberg EJ, Fidanza S, Sauaia A. Serologic testing for inflammatory bowel disease. J Pediatr 1999;134:447-52.
6. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998;115:822-9.
7. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001;96:730-4.
8. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000;47:487-96.
9. Vermeire S, Joossens S, Peeters M, Monsuur F, Mariën G, Bossuyt X, et al. Comparative study of ASCA (anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 2001;120:827-33.
10. Sendid B, Quinton J-F, Charrier G, Goulet O, Cortot A, Grandbastien B, et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol 1998;93:1306-10.
11. Vermeire S, Peeters M, Vlietinck R, Joossens S, Den Hond E, Bulteel V, et al. Anti-Saccaromyces cerevisiae antibodies (ASCA) in phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001;7:8-15.
12. Mielants H, Veys EM, Cuvelier C, De Vos M. Ileocolonoscopic findings in seronegative spondyloarthropathies. Br J Rheumatol 1988;27(suppl 2):95-105.
13. De Vos M, Cuvelier C, Mielants H, Veys E, Barbier F, Elewaut A. Ileocolonoscopy in seronegative spondyloarthropathy. Gastroenterology 1989;96:339-44.
14. Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 1995;22:2273-8.
15. Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 1995;22:2279-84.
16. De Keyser F, Elewaut D, De Vos M, De Vlam K, Cuvelier C, Mielants H. Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am 1998;24:785-813.
17. Demetter P, Vanhuysse JA, De Keyser F, Van Damme N, Verbruggen G, Mielants H, et al. Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis. J Pathol 2002;198:517-22.
18. De Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M. Spondyloarthopathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000;27:2860-5.
19. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991;34:1218-30.
20. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
22. Cuvelier C, Barbatis C, Mielants H, De Vos M, Roels H, Veys E. Histopathology of intestinal inflammation related to reactive arthritis. Gut 1987;28:394-401.
23. Cuvelier C, Mielants H, De Vos M, Veys E, Roels H. Major histocompatibility complex class II antigen (HLA-DR) expression by ileal epithelial cells in patients with seronegative spondyloarthropathy. Gut 1990;31:545-9.
24. Schatteman L, Mielants H, Veys EM, Cuvelier C, De Vos M, Gyselbrecht L, et al. Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol 1995;22:680-3.
25. Demetter P, Baeten D, De Keyser F, De Vos M, Van Damme N, Verbruggen G, et al. Subclinical gut inflammation in spondyloarthropathy patients is asociated with upregulation of the E-cadherin/catenin complex. Ann Rheum Dis 2000;59:211-16.
26. Demetter P, De Vos M, Van Damme N, Baeten D, Elewaut D, Vermeulen S, et al. Focal upregulation of E-cadherin-catenin complex in inflamed bowel mucosa but reduced expession in ulcer-associated cell lineage. Am J Clin Pathol 2000;114:364-70.
27. Elewaut D, De Keyser F, Cuvelier C, Lazarovits AI, Mielants H, Verbruggen G, et al. Distinctive activated cellular subsets in colon from patients with Crohn's disease and ulcerative colitis. Scand J Gastroenterol 1998;33:743-8.
28. Van Damme N, Elewaut D, Baeten D, Demetter P, Cuvelier C, Verbruggen G, et al. Gut mucosal T cell lines from patients with ankylosing spondylitis are enriched with αEβ7 integrin. Clin Exp Rheumatol 2001;19:681-7.
29. Van Damme N, De Vos M, Baeten D, Demetter P, Mielants H, Verbruggen G, et al. Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy. Ann Rheum Dis 2001;60:495-9.
30. Van Damme N, De Keyser F, Demetter P, Baeten D, Mielants H, Verbruggen G, et al. The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel disease. Clin Exp Immunol 2001;125:383-90.
31. Targan SR, Hanauer SB, Van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
32. Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000;356:1821-2.
33. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibodies to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59:428-33.
34. Van den Bosch F, Kruithof E, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002;46:755-65.